{"id":36135,"date":"2026-01-28T13:28:27","date_gmt":"2026-01-28T18:28:27","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=36135"},"modified":"2026-01-28T13:33:19","modified_gmt":"2026-01-28T18:33:19","slug":"where-are-the-most-active-u-s-district-courts-for-drug-patent-litigation-why-and-what-does-it-mean","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/where-are-the-most-active-u-s-district-courts-for-drug-patent-litigation-why-and-what-does-it-mean\/","title":{"rendered":"Where are the Most Active U.S. District Courts for Drug Patent Litigation, Why, and What Does it Mean?"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The geographic distribution of pharmaceutical patent litigation in the United States is currently undergoing its most significant realignment since the enactment of the Hatch-Waxman Act. For decades, the District of Delaware and the District of New Jersey have functioned as a virtual duopoly, handling the vast majority of Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) disputes.1<\/sup> However, recent data from 2024 and 2025 indicates a dramatic migration toward New Jersey, driven by a combination of judicial vacancies in Delaware, aggressive transparency requirements, and a perceived increase in patentee-friendly outcomes.1<\/sup><\/p>\n\n\n\n

For business development teams and intellectual property (IP) strategists, these shifts are not merely academic. The selection of a venue dictates the speed of the 30-month stay, the likelihood of a successful summary judgment, and the ultimate return on investment (ROI) for both innovator and generic firms.4<\/sup> As the industry approaches a massive “patent cliff” between 2025 and 2030, with an estimated $236 billion to $400 billion in annual revenue at risk, understanding the specific judicial mechanisms of these courts is essential for turning raw patent data into a competitive advantage.6<\/sup><\/p>\n\n\n\n

The Historical Dominance of the Pharma-Hub Districts<\/strong><\/h2>\n\n\n\n

The concentration of drug patent litigation in Delaware and New Jersey stems from the foundational corporate structure of the pharmaceutical industry. Delaware is the preferred state of incorporation for the majority of U.S. companies, while New Jersey serves as the operational headquarters for many of the world\u2019s largest pharmaceutical manufacturers.2<\/sup> This creates a natural nexus for personal jurisdiction under the standards established by the Supreme Court in TC Heartland<\/em>.9<\/sup><\/p>\n\n\n\n

Historically, these two districts managed over 80% of all ANDA cases in the nation.1<\/sup> This concentration allowed a specialized group of judges to develop deep expertise in the nuances of molecular biology and the complex regulatory framework of the Food and Drug Administration (FDA).2<\/sup> The institutional experience of these courts provides a level of predictability that is absent in districts where patent cases are a rarity.8<\/sup><\/p>\n\n\n\n

Distribution of ANDA Case Filings by District (2015-2024)<\/strong><\/h3>\n\n\n\n
Period<\/strong><\/td>District of Delaware<\/strong><\/td>District of New Jersey<\/strong><\/td>Other Districts<\/strong><\/td><\/tr>
2015<\/td>188 cases (40.5%)<\/td>188 cases (40.5%)<\/td>19.0%<\/td><\/tr>
2017-2021<\/td>>50% annually<\/td>~24% annually<\/td><20.0%<\/td><\/tr>
2021<\/td>68%<\/td>24%<\/td>8.0%<\/td><\/tr>
2024<\/td>42%<\/td>51%<\/td>7.0%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Data analysis from 2024 reveals that for the first time in a decade, the District of New Jersey has leapfrogged Delaware to become the primary forum for pharmaceutical patent challenges.1<\/sup> This transition represents a fundamental shift in how IP teams evaluate the risks and benefits of filing complaints in the “First State” versus the “Garden State.”<\/p>\n\n\n\n

The Great Migration: Why Litigants Are Flocking to New Jersey<\/strong><\/h2>\n\n\n\n

The sudden surge in New Jersey\u2019s caseload\u2014marked by a 100% year-over-year increase in ANDA filings in 2024\u2014is the result of several converging factors.2<\/sup> While Delaware was once the undisputed leader, a series of procedural and administrative changes has pushed litigants toward its northern neighbor.1<\/sup><\/p>\n\n\n\n

Judicial Bench Strength and Vacancies<\/strong><\/h3>\n\n\n\n

One of the most practical reasons for the shift is “bench strength.” The District of New Jersey currently maintains a full complement of active judges with no vacancies.3<\/sup> In contrast, the District of Delaware has faced several high-profile departures and elevations. The elevation of Judge Leonard P. Stark to the Federal Circuit and the retirement of experienced jurists like Gregory M. Sleet and Sue L. Robinson left a void in Delaware\u2019s specialized knowledge base.1<\/sup> When courts face vacancies, existing judges must absorb massive dockets, leading to delays that can jeopardize the resolution of a case before the 30-month stay expires.3<\/sup><\/p>\n\n\n\n

The Connolly Transparency Orders<\/strong><\/h3>\n\n\n\n

A more strategic driver of the migration is the series of standing orders issued by Chief Judge Colm F. Connolly in Delaware in April 2022.13<\/sup> These orders require litigants to disclose the identity and financial stakes of third-party litigation funders, as well as comprehensive details regarding the ownership chain of all non-governmental parties.13<\/sup><\/p>\n\n\n\n

For many pharmaceutical companies and the private equity groups that fund them, this level of disclosure is unpalatable. Transparency regarding funding can reveal a party\u2019s financial “runway,” potentially providing an opponent with leverage in settlement negotiations.14<\/sup> By moving cases to New Jersey, where such disclosures are not currently required by standing order, litigants can maintain a higher degree of confidentiality over their strategic and financial arrangements.2<\/sup><\/p>\n\n\n\n

“Disclosure of litigation funding gives an advantage to the defense counsel in knowing how long it can run the meter of its adversary before bringing the adversary to its knees. Courts should decide cases with third-party litigation funding the same way as those without: on the law and the facts.” \u2014 Ken Rosen, Industry Attorney 14<\/sup><\/p>\n\n\n\n

Comparative Win Rates for Patentees<\/strong><\/h3>\n\n\n\n

Data from the past three years also indicates that New Jersey has become a more favorable environment for brand-name drug manufacturers. In 2023, the win rate for patentees in New Jersey reached 21%, the highest of the decade.1<\/sup> In contrast, Delaware\u2019s patentee win rate for the same period was only 3%.1<\/sup> While these numbers vary by year, the trend has signaled to innovator firms that New Jersey may offer a more pragmatic and supportive environment for defending their patent portfolios.1<\/sup><\/p>\n\n\n\n

The Role of the District of Delaware: A Changing Fortress<\/strong><\/h2>\n\n\n\n

Despite the recent shift, the District of Delaware remains a critical center of power. Its judges manage more patent cases per authorized judgeship than almost any other district in the nation.12<\/sup> The court’s procedures, while increasingly rigid under the new standing orders, are specifically tailored for efficiency in complex litigation.4<\/sup><\/p>\n\n\n\n

Summary Judgment and Trial Efficiency<\/strong><\/h3>\n\n\n\n

A defining feature of Delaware\u2019s pharmaceutical docket is the rarity of summary judgment.4<\/sup> The court\u2019s experienced bench often prefers to let cases proceed to a full bench trial, where they can evaluate the technical merits and witness credibility in detail.4<\/sup> This “do not pass go” approach can be frustrating for litigants seeking an early exit, but it ensures a high-quality, appellate-ready record.4<\/sup> Delaware judges have presided over more ANDA cases than all other federal courts combined over the last decade, creating a massive body of precedent that provides a roadmap for future litigation.2<\/sup><\/p>\n\n\n\n

Top Judges by Case Volume (2024-2025 Statistics)<\/strong><\/h3>\n\n\n\n
Judge<\/strong><\/td>District<\/strong><\/td>Cases Assigned (2024)<\/strong><\/td>Key Focus<\/strong><\/td><\/tr>
James Rodney Gilstrap<\/td>E.D. Texas<\/td>~800<\/td>General Patent\/High Tech 19<\/sup><\/td><\/tr>
Richard Gibson Andrews<\/td>D. Delaware<\/td>High Volume<\/td>Pharmaceutical\/ANDA 2<\/sup><\/td><\/tr>
Gregory Brian Williams<\/td>D. Delaware<\/td>High Volume<\/td>Pharmaceutical\/ANDA 2<\/sup><\/td><\/tr>
Maryellen Noreika<\/td>D. Delaware<\/td>High Volume<\/td>Pharmaceutical\/ANDA 2<\/sup><\/td><\/tr>
Brian R. Martinotti<\/td>D. New Jersey<\/td>High Volume<\/td>Pharmaceutical\/ANDA 2<\/sup><\/td><\/tr>
Michael A. Shipp<\/td>D. New Jersey<\/td>High Volume<\/td>Pharmaceutical\/ANDA 2<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

While Judge Gilstrap in Texas remains the national leader in total patent case volume, his docket is dominated by high-tech disputes and NPE activity.19<\/sup> For the pharmaceutical professional, the “power brokers” are the Delaware and New Jersey jurists who manage the specialized life sciences dockets.2<\/sup><\/p>\n\n\n\n

The Impact of TC Heartland on Geographic Strategy<\/strong><\/h2>\n\n\n\n

The 2017 Supreme Court decision in TC Heartland LLC v. Kraft Food Group Brands LLC<\/em> fundamentally narrowed the options for venue selection.9<\/sup> Before this ruling, a plaintiff could sue a domestic corporation in any district where the defendant was subject to personal jurisdiction\u2014essentially wherever the product was sold.9<\/sup> Post-TC Heartland<\/em>, venue is only proper in the district where the defendant resides (its state of incorporation) or where it has a regular and established place of business and has committed an act of infringement.9<\/sup><\/p>\n\n\n\n

For the pharmaceutical industry, this decision initially reinforced Delaware\u2019s dominance, as a high percentage of both brand-name and generic companies are incorporated there.2<\/sup> However, it also created significant challenges for innovators seeking to sue multiple generic challengers in a single forum.10<\/sup> If different generic manufacturers are incorporated in different states and do not share a common place of business, the innovator may be forced to file “mirror” suits in multiple districts.10<\/sup> This increases costs and creates the risk of inconsistent rulings on the same patent, as different judges may reach different conclusions on claim construction or validity.10<\/sup><\/p>\n\n\n\n

The BPCIA and the Second Wave of Biologics Litigation<\/strong><\/h2>\n\n\n\n

While the Hatch-Waxman Act governs small-molecule drugs, the BPCIA provides the framework for biosimilars.25<\/sup> Biosimilar litigation is even more concentrated than ANDA litigation, with Delaware and New Jersey handling over 60% of all cases filed since the act’s inception in 2010.11<\/sup><\/p>\n\n\n\n

The industry is currently transitioning from the “first wave” of biosimilars\u2014targeting early products like Humira and Rituxan\u2014to a “second wave” targeting newer biologics such as Stelara (ustekinumab), Prolia\/Xgeva (denosumab), and Eylea (aflibercept).27<\/sup><\/p>\n\n\n\n

Cumulative BPCIA Cases by District<\/strong><\/h3>\n\n\n\n
District Court<\/strong><\/td>Number of Cases<\/strong><\/td>Percentage<\/strong><\/td><\/tr>
District of Delaware<\/td>20<\/td>37.0% 11<\/sup><\/td><\/tr>
District of New Jersey<\/td>13<\/td>24.1% 11<\/sup><\/td><\/tr>
Northern District of West Virginia<\/td>6<\/td>11.1% 11<\/sup><\/td><\/tr>
Southern District of Florida<\/td>3<\/td>5.6% 11<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The emergence of the Northern District of West Virginia as a significant venue is largely due to the historic presence of Mylan (now Viatris) in the region.11<\/sup> Judge Thomas Shawn Kleeh has presided over all six BPCIA cases in that district, making him a central figure in the multi-district litigation involving Regeneron’s drug Eylea.11<\/sup><\/p>\n\n\n\n

Case Study: The Aflibercept Battle in West Virginia<\/strong><\/h2>\n\n\n\n

The aflibercept litigation provides a clear example of how a specialized venue can dictate the pace of market entry.28<\/sup> Regeneron Pharmaceuticals has engaged in an extensive series of disputes in the Northern District of West Virginia against multiple biosimilar competitors, including Samsung Bioepis, Formycon, and Mylan.28<\/sup><\/p>\n\n\n\n

In early 2025, the Federal Circuit affirmed several preliminary injunctions issued by the West Virginia district court, preventing these competitors from marketing their versions of Eylea.28<\/sup> These rulings were critical because they demonstrated that the “stability family” of patents could withstand initial validity challenges.29<\/sup> However, the court denied a similar injunction against Amgen, finding that Regeneron had not established a likelihood of success on the merits for that specific challenge.28<\/sup> This underscores a vital point: even in a favorable venue, the specific technical arguments and patent claims at issue can lead to divergent outcomes.<\/p>\n\n\n\n

The Economic Rationale of the 30-Month Stay<\/strong><\/h2>\n\n\n\n

In pharmaceutical litigation, the primary goal is often time, not just a final legal victory. The 30-month stay is the most potent immediate tool for brand-name companies.6<\/sup> By filing a suit within 45 days of a Paragraph IV notification, the brand company triggers an automatic freeze on FDA approval for the generic product.5<\/sup><\/p>\n\n\n\n

The ROI of this stay is astronomical for blockbuster drugs. For a product generating $10 million in revenue every day, the 30-month stay is worth approximately $9 billion in protected revenue.7<\/sup> This creates a massive incentive for brand companies to file suit in districts known for efficient case management, ensuring the litigation can be resolved\u2014or at least kept active\u2014until the stay expires.6<\/sup><\/p>\n\n\n\n

Financial Impacts of Patent Expiration (2025-2030 Estimates)<\/strong><\/h3>\n\n\n\n
Financial Metric<\/strong><\/td>Industry Impact<\/strong><\/td><\/tr>
Global Revenue at Risk<\/td>$236B to $400B 6<\/sup><\/td><\/tr>
Average Market Cap at Stake per PIV Filing<\/td>$4.3 Billion 6<\/sup><\/td><\/tr>
Revenue Drop upon Generic Entry<\/td>80% to 90% 33<\/sup><\/td><\/tr>
First-to-File 180-Day Revenue Potential<\/td>Hundreds of Millions 6<\/sup><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

For generic manufacturers, the 180-day exclusivity period is the “holy grail” of litigation.6<\/sup> This period allows the first-to-file generic to market its product with almost no competition, capturing a significant portion of the brand’s original market share at a much higher price than what is possible after subsequent generic entrants arrive.7<\/sup><\/p>\n\n\n\n

The Actavis Ruling: A Tax Advantage for Generic Challengers<\/strong><\/h2>\n\n\n\n

A pivotal 2025 ruling by the Federal Circuit has altered the financial landscape for patent challengers. In Actavis Laboratories FL, Inc. v. United States<\/em>, the court held that legal expenses incurred in defending Hatch-Waxman lawsuits are deductible as “ordinary and necessary business expenses” in the year they are incurred.36<\/sup><\/p>\n\n\n\n

Historically, the IRS had argued that these multi-million-dollar expenses should be capitalized, meaning they could only be deducted slowly over the life of the approved drug.36<\/sup> By allowing an immediate deduction, the court has significantly improved the cash flow and short-term financial viability of generic companies engaging in “at-risk” litigation.36<\/sup> This ruling also corrected a historical imbalance, as brand-name companies have always been permitted to deduct their costs for enforcing their patent rights.37<\/sup><\/p>\n\n\n\n

Competitive Intelligence: Turning Data into Advantage<\/strong><\/h2>\n\n\n\n

In this specialized judicial environment, the ability to anticipate moves is paramount. Platforms like DrugPatentWatch<\/strong> have become essential tools for business and IP teams to monitor the shifting geography of litigation.39<\/sup> By providing comprehensive databases of patent expirations, Paragraph IV notifications, and litigation outcomes, DrugPatentWatch<\/strong> allows companies to identify “weak links” in a competitor’s patent portfolio long before a complaint is filed.6<\/sup><\/p>\n\n\n\n

For generic firms, these tools help time their submissions to maximize the chance of securing first-to-file exclusivity.7<\/sup> For innovators, they serve as a defensive monitoring system, identifying which generic competitors are most likely to challenge a specific patent and in which district they are most likely to be sued.31<\/sup> The integration of these datasets into a company\u2019s broader R&D and business development strategy allows for more accurate forecasting of revenue streams and a more disciplined approach to capital allocation.42<\/sup><\/p>\n\n\n\n

Procedural Nuances: Delaware vs. New Jersey Local Rules<\/strong><\/h2>\n\n\n\n

The preference for one district over another often comes down to the “fine print” of local rules. New Jersey’s Local Patent Rules are specifically designed to manage the unique sequencing requirements of Hatch-Waxman and BPCIA cases.44<\/sup> These rules dictate the timing for:<\/p>\n\n\n\n

    \n
  1. Initial disclosures of non-infringement and invalidity contentions.45<\/sup><\/li>\n\n\n\n
  2. The submission of discovery plan topics including ANDA product research and development documents.46<\/sup><\/li>\n\n\n\n
  3. The format and timing of Markman hearings for claim construction.45<\/sup><\/li>\n<\/ol>\n\n\n\n

    Delaware, by contrast, does not have uniform local patent rules, leaving much more discretion to individual judges.2<\/sup> While this flexibility allows experienced Delaware judges to tailor schedules for specific cases, it also introduces a level of uncertainty that some litigants prefer to avoid.2<\/sup> The “predictability” of New Jersey’s rules is a significant “pull” factor for companies seeking a disciplined litigation timeline.47<\/sup><\/p>\n\n\n\n

    Future Outlook: The Resurgence of the Western District of Texas?<\/strong><\/h2>\n\n\n\n

    While the Northeast remains the heart of pharmaceutical litigation, the Western District of Texas\u2014once the busiest patent court in the world under Judge Alan Albright\u2014is attempting a resurgence.20<\/sup> Although modifications to case assignment rules in 2024 aimed to reduce the concentration of cases before Judge Albright, the district remains popular for tech-heavy medical device and biotechnology patent disputes.49<\/sup><\/p>\n\n\n\n

    Recent data from 2025 shows that the Western District of Texas is again increasing in popularity, although it remains a “distant second” to the Eastern District of Texas for NPE filings and has yet to significantly challenge the Delaware\/New Jersey dominance in the ANDA space.48<\/sup> For companies developing advanced therapies involving AI or specialized hardware, the Western District of Texas may become a more relevant venue in the coming years.50<\/sup><\/p>\n\n\n\n

    Strategic Implications for Global Competition<\/strong><\/h2>\n\n\n\n

    Location choice in patent litigation is ultimately a resource allocation decision.52<\/sup> Suing country-by-country is prohibitively expensive; therefore, firms must concentrate their efforts in “reputable courts” that can send a strong signal to competitors globally.52<\/sup> A verdict from a highly respected judge in Delaware or New Jersey can often pressure opponents into a global settlement, effectively resolving disputes in multiple international markets simultaneously.52<\/sup><\/p>\n\n\n\n

    This “signaling” effect is particularly important as the world becomes more harmonized in its patent standards.52<\/sup> As pharmaceutical institutions become more homogeneous across the U.S. and Europe, the outcomes in one location increasingly dictate firm behavior elsewhere.52<\/sup><\/p>\n\n\n\n

    Key Takeaways<\/strong><\/h2>\n\n\n\n